e-Therapeutics plc - Expansion of Scientific Advisory Board
("e-therapeutics" or the "Company")
e-therapeutics strengthens Scientific Advisory Board
e-therapeutics plc (AIM: ETX.L, "e-therapeutics'" or "the Company"), today announces the expansion of its Scientific Advisory Board (SAB) with the appointment of Dr
The appointments follow the establishment of the SAB in May of 2020 with the initial appointment of Dr
"I am delighted to welcome Bill and John to the e-therapeutics Scientific Advisory Board. We believe that their high calibre experience and guidance will be of significant value as the Company progresses its strategy to achieve its future commercial goals."
"We are honoured and excited to have convened such a distinguished Scientific Advisory Board. Paul, Bill and John all have considerable industry experience, and we look forward to their strategic advice and insight on transforming the drug discovery process as we continue to grow e-therapeutics whilst exploring new areas such as RNAi."
For further information, please contact:
Tel: +44 (0)1993 883 125
Numis Securities Limited
Tel: +44 (0) 207 260 1000
Tel: +44 (0) 203 727 1000
Email: [email protected]
About e-therapeutics plc
e-therapeutics plc is an
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.
Quick facts: e-Therapeutics PLC
Market Cap: £60.24 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE